| Tap a line for its trend | Currentlast close | FY24Mar 2024 | FY23Mar 2023 | FY22Mar 2022 |
|---|
| — | — | — | 10.9 | |
| 98.1 | 98.1 | — | — | |
| 307 | 307 | 251 | 456 | |
| — | +22.4% | −45.0% | — | |
| 66.6 | 66.6 | 60.3 | 172 | |
| 21.7% | 21.7% | 24.0% | 37.7% | |
| 47.1 | 47.1 | 45.4 | 161 | |
| — | — | — | 120 | |
| — | — | — | 26.3% | |
| — | — | — | ₹115.70 | |
| — | — | 42.2 | 63.1 | |
| −29.8 | −29.8 | −47.7 | −55.2 | |
| — | — | −5.5 | 7.9 | |
From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY22 31/03/2022 | FY23 31/03/2023 | FY24 31/03/2024 | Current last close | |
|---|---|---|---|---|---|
| - Cash, Equiv & ST Investments | 10.9 | — | — | — | |
| + Total Debt | — | — | 98.1 | 98.1 | |
| Revenue | 456.1 | 251.0 | 307.2 | 307.2 | |
| Growth %, YoY | — | -45.0 | +22.4 | — | |
| EBITDA | 171.7 | 60.3 | 66.6 | 66.6 | |
| Margin % | 37.65 | 24.02 | 21.69 | 21.69 | |
| EBIT | 161.1 | 45.4 | 47.1 | 47.1 | |
| Net Income | 120.0 | — | — | — | |
| Margin % | 26.32 | — | — | — | |
| EPS, Adj (current shares) | 115.70 | — | — | — | |
| Cash from Operations | 63.1 | 42.2 | — | — | |
| Capital Expenditures | -55.2 | -47.7 | -29.8 | -29.8 | |
| Free Cash Flow | 7.9 | -5.5 | — | — | |
Figures from the company's filings with NSE
Its debt-to-equity ratio was 0.43 on 31 March 2024.
No. Kwality Pharmaceuticals had borrowings of ₹98.1 crore on 31 March 2024 (consolidated balance sheet), a debt-to-equity ratio of 0.43. Its cash and current investments were ₹1.4 crore, so its net debt was ₹96.8 crore.
Kwality Pharmaceuticals' debt-to-equity ratio was 0.43 on 31 March 2024: borrowings of ₹98.1 crore against total equity of ₹226 crore.
Kwality Pharmaceuticals' net worth — shareholders' equity in its consolidated balance sheet — was ₹226 crore on 31 March 2024.
From Kwality Pharmaceuticals' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
